Contact Us
800.227.0627

Bridged Nucleic Acids - BNA - TEW

 
Print Print
Please select subject area:
Bridged Nucleic Acids - BNA
Biosyn
Highly nuclease resistance and thermodynamically stable 2′-O,4′-C-Ethylene-bridged Nucleic Acid (ENA) as a promising candidate for antisense therapy
01/12/2024
Biosyn
Therapeutic tiny or short modified antisense oligonucleotides (Tiny ASOs) can block gene expression or modulate splice-switching!
11/06/2023
Biosyn
Therapeutic Antisense Oligonucleotides (ASOs) and their Modifications
10/25/2023
Biosyn
A triplex-forming bridged nucleic acid oligonucleotide peptide conjugate increases transfection efficiency by targeting the nucleus
12/20/2022
Biosyn
Phosphate modifications for gene silencing with RNAi
03/31/2021
Biosyn
5'-Phosphate modifications for gene silencing with RNAi
03/31/2021
Biosyn
Sugar modifications for gene silencing using siRNA
03/26/2021
Biosyn
Therapeutic peptide discovery via high throughput screening of random peptide phage-display library
03/24/2021
Biosyn
Tumor drug penetration measurement reveals limited distribution of fluor-conjugated Herceptin antibody in a mouse breast cancer model
03/08/2021
Biosyn
Fatty acid conjugated BNA antisense oligonucleotides exhibit enhanced uptake into muscle
03/04/2021
Biosyn
FDA approves second RNA interference-inducing siRNA oligonucleotide drug for treating acute hepatic porphyria, raising the prospect for cancer therapy
02/23/2021
Biosyn
Antisense targeting of SARS-CoV-2 virus with BNAs
02/12/2021
Biosyn
Potential use of mRNA encoding scFv recognizing amyloid-beta peptide to treat Alzheimer's disease
02/11/2021
Biosyn
Point Mutation Detection with Bridged Nucleic Acids (BNAs)
02/08/2021
Biosyn
Argonaute-2 can bind metabolic stable siRNAs
02/03/2021
1234567
imgscroll